Application of circulating tumor DNA detection in prediction of curative effect of non-small cell lung cancer
10.3760/cma.j.cn115355-20220711-00437
- VernacularTitle:循环肿瘤DNA检测在非小细胞肺癌疗效预测中的应用
- Author:
Wenjue ZHANG
1
;
Wei JIANG
;
Lyuhua WANG
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院深圳医院放射治疗科，深圳 518116
- Keywords:
Carcinoma, non-small-cell lung;
Circulating tumor DNA;
Radiotherapy, computer-assisted;
Immunotherapy;
Prognosis
- From:
Cancer Research and Clinic
2022;34(8):623-626
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the malignant tumor with the highest mortality in the world, of which non-small cell lung cancer (NSCLC) accounts for about 80%. The orderly combination of surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy is currently the main treatment modality for NSCLC. Liquid biopsy has been increasingly used in clinical practice in recent years due to its advantages of being non-invasive and overcoming tumor heterogeneity, of which circulating tumor DNA (ctDNA) is one of the most commonly used analytical indicators, and ctDNA detection may play a role in the treatment of NSCLC. This article reviews new developments in the use of ctDNA for prognostic assessment, recurrence monitoring and efficacy prediction in NSCLC patients.
